At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
Methylene Blue +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
The University of Texas Health Science Center at San Antonio·interventional·Posted Mar 5, 2015·Updated Sep 19, 2024
In Brief
A Phase 2 clinical trial evaluating Methylene Blue, FD&C Blue # 2, and 1 other intervention for Mild Cognitive Impairment and 4 related conditions. Completed, enrolled 117 participants across 1 site.
Detailed Summary
A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and 12-week administration of USP methylene blue (MB) on cerebral blood flow, functional connectivity, memory and attention cognitive abilities using fMRI and behavioral measures in healthy aging, mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment, MCI, Aging, Alzheimer's Disease, AD
CountriesUnited States
CollaboratorsTexas Alzheimer's Research and Care Consortium
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartJul 2015
Primary CompletionApr 2022
Study CompletionJul 2023
TodayJul 2026
First PostedMar 5, 2015
Enrollment StartJul 1, 2015
Primary CompletionApr 21, 2022
Study CompletionJul 1, 2023
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 11.3 years ago
Interventions
Methylene Bluedrug
FD&C Blue # 2drug
Phenazopyridine hydrochloridedrug